Rational Design and Development of an Acyclic Chelator H 4 pyox for Theranostic Radiometal Labeling under Mild Conditions

Le résumé fourni par la source

Integrated diagnostic and therapeutic nuclear medicine requires chelators that coordinate multiple radionuclides efficiently under mild conditions. Herein, we developed H 4 pyox, an acyclic chelator with a preorganized cavity designed to balance rapid kinetics with a high thermodynamic stability. H 4 pyox achieves roughly quantitative radiochemical yields with various diagnostic and therapeutic radionuclides, 68 Ga, 86 Y, 177 Lu, etc., within 10 min at ambient temperature, whereas DOTA requires heating (>90 °C). Notably, H 4 pyox maintains an ∼100% yield for 177 Lu at concentrations as low as 10 –7 M, significantly outperforming DOTA. To facilitate clinical translation, an activated ester, H 4 pyox-NHS, was synthesized for efficient bioconjugation. The [ 177 Lu]Lu-pyox complex showed excellent stability in saline and mouse serum over 7 days of incubation, which is comparable to that of the [ 177 Lu]Lu-DOTA complex. Density functional theory calculations revealed that structural preorganization and high donor nucleophilicity underpin its rapid kinetics. Moreover, in vivo single-photon emission computed tomography/computed tomography imaging confirmed the stability of the [ 177 Lu]Lu-pyox complex and a dual metabolic excretion pathway (renal/hepatobiliary) without bone accumulation. These results support the potential of H 4 pyox for radiopharmaceutical development and provide a complementary choice in the design of metal-based radiopharmaceuticals and in the tuning of their pharmacokinetic properties─especially for targeting vectors with poor thermal stability.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.